Analystreport

Coherus BioSciences, Inc. (NASDAQ: CHRS) is now covered by analysts at Citigroup Inc.. They set a "buy" rating and a $12.00 price target on the stock.

Coherus BioSciences, Inc.  (CHRS) 
Last coherus biosciences, inc. earnings: 2/27 04:01 pm Check Earnings Report
US:NASDAQ Investor Relations: investors.coherus.com